financetom
Business
financetom
/
Business
/
Market Chatter: SEC Investigates Publicly Traded Tech Firms' Foreign Partners to Weed Out Corruption
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: SEC Investigates Publicly Traded Tech Firms' Foreign Partners to Weed Out Corruption
Apr 3, 2024 5:49 AM

08:27 AM EDT, 04/03/2024 (MT Newswires) -- The Securities and Exchange Commission is investigating publicly traded tech firms' relationships with distributors and other partners outside the US in a move to combat corruption, Bloomberg reported Wednesday, citing unnamed sources.

As part of its enforcement of the Foreign Corrupt Practices Act, the regulator has been contacting tech companies to find out if they have worked with a list of dozens of intermediaries, some of which have been implicated in other investigations, Bloomberg reported.

The Foreign Corrupt Practices Act prohibits bribing foreign officials, and requires publicly traded companies to maintain accurate books and records to provide assurances that deals are conducted and assets are accounted for in accordance with generally accepted accounting principles.

The FCPA, which can apply to prohibited conduct anywhere in the world, extends to publicly traded companies as well as their officers, directors, employees, agents, and stockholders.

Representatives from the SEC did not immediately respond to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Invivyd's Pemgarda Injection to Prevent Covid Available in US -- Shares Rise After Hours
Invivyd's Pemgarda Injection to Prevent Covid Available in US -- Shares Rise After Hours
Apr 4, 2024
04:39 PM EDT, 04/04/2024 (MT Newswires) -- Invivyd ( IVVD ) said late Thursday its Pemgarda injection to prevent coronavirus is available for purchase in the US. Pemgarda obtained emergency use authorization from the US Food and Drug Administration on March 22 for the prevention of COVID-19 in some adults and adolescents with moderate-to-severe immune compromise, the company said. Pemgarda...
Boundless Bio Insider Bought Shares Worth $3,200,000, According to a Recent SEC Filing
Boundless Bio Insider Bought Shares Worth $3,200,000, According to a Recent SEC Filing
Apr 4, 2024
04:38 PM EDT, 04/04/2024 (MT Newswires) -- Keith Crandell, 10% Owner, on April 02, 2024, executed a purchase for 200,000 shares in Boundless Bio ( BOLD ) for $3,200,000. Following the Form 4 filing with the SEC, Crandell has control over a total of 1,181,766 shares of the company, with 1,181,766 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1782303/000095017024041842/xslF345X03/ownership.xml ...
United Therapeutics Insider Sold Shares Worth $1,394,248, According to a Recent SEC Filing
United Therapeutics Insider Sold Shares Worth $1,394,248, According to a Recent SEC Filing
Apr 4, 2024
04:39 PM EDT, 04/04/2024 (MT Newswires) -- Paul A Mahon, Executive Vice President & General Counsel, on April 04, 2024, sold 6,000 shares in United Therapeutics ( UTHR ) for $1,394,248. Following the Form 4 filing with the SEC, Mahon has control over a total of 36,710 shares of the company, with 36,710 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1082554/000141588924010279/xslF345X03/form4-04042024_040401.xml ...
Kura Sushi Reports Mixed Q2 Results: EPS Misses, Sales Beat
Kura Sushi Reports Mixed Q2 Results: EPS Misses, Sales Beat
Apr 4, 2024
Kura Sushi USA, Inc. ( KRUS ) reported its second-quarter financial results after the bell Thursday. Here's a look at the details.  The Details: The company reported quarterly losses of 9 cents per share, missing the analyst estimate of losses of 3 cents per share. Quarterly sales came in at $57.29 million, beating the $56.64 million analyst consensus estimate. “I‘m...
Copyright 2023-2026 - www.financetom.com All Rights Reserved